Navigation Links
With the Recent Launch of Novartis's Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
Date:12/13/2010

EXTON, Pa., Dec. 13, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. finds that with the introduction of Novartis' Gilenya, the first oral disease-modifying agent (DMA) for the treatment of multiple sclerosis (MS), neurologists anticipate major shifts in the landscape of the MS market. One month after the launch of Gilenya, trial and uptake of Extavia, a DMA launched by Novartis one year earlier, continues to be tempered due to the perception that Extavia is a "me too" agent -a perception made even more noticeable by the availability of the new and unique DMA, Gilenya. In fact, compared to previous waves, both current and anticipated patient share of Extavia have decreased due in part to a drop in the number of high prescribers of Extavia.

The recently released fourth and final wave of the LaunchTrends®: Extavia report series finds that the small amount of Extavia use is mostly driven by out-of-pocket cost concerns with other DMAs and that managed care reimbursement is playing less of a role compared to the role it played in the first year of Extavia's commercial availability. In fact, perceptions of the managed care process for Extavia have declined since earlier waves. While Novartis detailing seems to be primarily focused on Gilenya, neurologists who were recently detailed on Extavia are more likely to have experience with the DMA. While anticipated prescribing of Gilenya is expected to rise substantially over the next six months, surveyed neurologists believe that any change in their prescribing of Extavia will be minimal.

LaunchTrends®: Extavia is a four wave syndicated report series designed to track the uptake of Novartis's Extavia at one month, six months, nine months and one year following its commercial availability. In the current wave of research which measures Extavia's market impact after one year, BioTrends surveyed 76 neurologists and conducted qualitative interviews with a subset of
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
2. Water Street Health Care Partners Completes Agreement With Gentiva Health Services to Acquire Majority Ownership of CareCentrix
3. [video] Wall St. Networks 3-Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: IMMU, KYUS
4. [video] Wall St. Networks 3-Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: GTHR, BHRT, AGO
5. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
6. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
7. New Report Provides Expert Analysis of Recent Advances and Setbacks in Parkinsons Disease Drug Development
8. Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
9. American Oriental Bioengineering Comments on Recent Property Purchase
10. Recent Advances in Organic Chemistry Using Real-Time In Situ FTIR
11. Recent Reports Regarding Mercury and High Fructose Corn Syrup Flawed and Misleading
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... (PRWEB) July 28, 2014 According ... Transparency Market Research "Regenerative Medicine (Bone and Joint) ... and Tissue Engineering; By Applications - Bone Graft ... Others) - Global Industry Analysis, Size, Share, Growth, ... regenerative medicine (bone and joint) market was valued ...
(Date:7/28/2014)... , July 28, 2014  David Hardison, ... ConvergeHEALTH by Deloitte , has been elected chairman ... Standards Consortium, a non-profit working to establish common ... particularly as it relates to electronic health records. ... CDISC,s mission of collaborating with organizations across the ...
(Date:7/28/2014)... July 28, 2014 The global market ... by 2020, according to a new study by Grand ... rising demand for effective vaccines and drugs in an ... medical needs is expected to drive market demand over ... enhance agricultural productivity via the use of genetically engineered ...
(Date:7/26/2014)... 26, 2014 Canada Endoscopy Visualization ... data on the Canada Endoscopy Visualization Systems market. ... dollars, volume (in units) and average prices (in ... Visualization Systems, Mid-Range Endoscopy Visualization Systems and Low-End ... http://www.marketresearchreports.biz/analysis/213254 . , The report also provides ...
Breaking Biology Technology:Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5
... LEXINGTON, Mass., Feb. 14, 2012 Avaxia Biologics, ... drugs that act locally within the gastrointestinal tract, ... million Series A angel-led financing.  Cherrystone Angels of ... from Beacon Angels, Boston Harbor Angels, Launchpad Venture ...
... a task force comprised of Indianapolis business, academic and ... Indiana,s life sciences sector that would catapult the state,s ... into a 21st-century hub for biotechnology and medical technology. ... state into the national spotlight as a leader and ...
... Calif., Feb. 13, 2012 Amgen (NASDAQ: AMGN ... 9:30 a.m. Eastern Standard Time  on Thursday, Feb. 16, 2012, ... M. Peacock, executive vice president and chief financial officer at ... presentation can be accessed from the Events Calendar on Amgen,s ...
Cached Biology Technology:Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease 2Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease 3BioCrossroads Commemorates Decade of Collaboration, Success for Indiana Life Sciences Sector 2BioCrossroads Commemorates Decade of Collaboration, Success for Indiana Life Sciences Sector 3
(Date:7/28/2014)... Roald Amundsen became the first man to reach the ... years later, an international team of scientists led by ... proven that air pollution from industrial activities arrived long ... from widely spaced locations around the Antarctic continent, including ... and precise reconstruction to date of lead pollution over ...
(Date:7/27/2014)... asteroid strike that wiped them out if it had ... say. , A fresh study using up-to-date fossil records ... a new narrative of the prehistoric creatures, demise, some ... the few million years before a 10km-wide asteroid struck ... This included extensive volcanic activity, changing sea levels and ...
(Date:7/27/2014)... discovered a new species of mayfly in the southern Western ... In fact, this is the first time that any mayfly ... in peninsular India. , The new species, called Labiobaetis ... for his substantial contribution to the understanding of the Ephemeroptera ... a study that describes the new mayfly in the ...
Breaking Biology News(10 mins):Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3Dinosaurs fell victim to perfect storm of events, study shows 2
... their ongoing studies of how yeast (fungi) can infect ... the Life Sciences and Bioengineering Center at Worcester Polytechnic ... that yeast produce a hormone previously known to be ... hormone in sufficient quantity within the yeast,s immediate environment ...
... the University of Illinois have developed a new, more ... emissions that results from changes in land use. ... Change Biology , takes into account many factors not ... There is an urgent need to accurately assess whether ...
... CHAPEL HILL When the arteries delivering oxygen to our ... is almost always a stroke, heart attack or damage to ... But the severity of tissue injury or destruction from ... may depend in large part on whose circulatory system has ...
Cached Biology News:Discovery: Yeast make plant hormone that speeds infection 2Researchers calculate the greenhouse gas value of ecosystems 2Researchers calculate the greenhouse gas value of ecosystems 3Study pinpoints new role of molecule in the health of body's back-up blood circulation 2Study pinpoints new role of molecule in the health of body's back-up blood circulation 3Study pinpoints new role of molecule in the health of body's back-up blood circulation 4
Kit includes your choice of reagents for labeling 3 x 10 9 cells and EasySep magnet....
... the efficient enrichment of functional endoplasmic ... cell culture. The isolated ER are ... metabolic pathway analysis. Metabolic abnornalities of ... children, cystic fibrosis and many more ...
... for stabilizing 50g of purified RNA samples for ... delivers all of the advantages and applications you ... the RNA can be used for enzymatic applications ... has been optimised for the stabilization of aqueous ...
Human SEAP ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
Biology Products: